ID: MRFR/Pharma/2289-CR | 157 Pages | Published By Kinjoll Dey on February 2021
The renal disease market is projected to reach USD 89,070 Million by 2030 at 11.20% CAGR during the forecast period 2022-2030. When the kidney cannot function properly, this renal disease occurs. Hence, it is also known as kidney disease. Depending upon the different numerous conditions, different types of symptoms, and signs, different types of kidney diseases are formed.
In this vast population, most of the people are suffering from renal disease, diabetes, and hypertension. The growth of geriatric people is expected to increases the chronic kidney disease market growth. Apart, the healthcare cost and stringent regulatory policies are going to be increasing.
COVID-19 pandemic has everyone’s life in different ways. Due to the government regulations and lockdowns, people stayed in the home itself, and hence the demand for home dialysis increases. Most of the affected people of COVID-19 are people suffering from diabetes and ESRD compared to healthy people. The condition with reduced kidney function leads to chronic kidney disease which may lead to end-stage renal disease (ESRD).
Worldwide, all countries are taking necessary steps to ensure the safety of the patients amid the crisis. Additionally, the government issued the guidelines and Interim Additional Guidance for Infection Prevention and Control (IPC) recommendations for the patients who are suspected and confirmed of the coronavirus disease.
Diagnosis of Blood Test for high growth over the forecast period
A blood test is a major test for the diagnosis of kidney disease which shows detailed information about kidneys working conditions. Due to the increase of Chronic Kidney Disease (CKD) the demand for blood tests is expected to increase. Moreover, the ESRD (End-Stage Renal Disease) is also increasing at a significant rate.
In 2017, it is recorded that 697.5 million people with CKD struggle. After causing CKD, it may develop and lead to ESRD which tends to kidney failure. In Singapore, from 2007 to 2017 the prevalence of CKD increases from 12% to 17% and is further expected to increase by approximately 24% by 2035. Due to the rise of chronic kidney disease, the market is expected to be high over the forecast period. An increasing number of patients with hypertension and diabetes, high prevalence of ESRD, and rapid growth in the geriatric population are major drivers of the market.
Rise of Healthcare cost and stringent regulatory policies
By increasing the cost of the healthcare sector and stringent regulatory policies are the restraints of the market growth. By reducing the cost of the healthcare sector, it may be expected to increase the growth of renal disease treatment.
Expansion in Developing Economies
The developing and developed countries launched advanced technological products in the market to reduce the increase in renal failures. This new expansion increases the end-stage renal disease market growth.
Reduction of the cost over the healthcare sector is the major challenge of the end-stage market growth.
The technologically advanced products like low maintenance dialysis equipment for diagnosis of Chronic Kidney Disease and artificial kidney helps to the growth of the end-stage renal disease market.
Study Objectives -
Globally, Renal disease stages have been segmented into two types of diseases like chronic kidney disease and end-stage renal disease.
Based on Treatment Type
The renal disease market is segmented into dialysis, medication, and kidney transplantation. Further dialysis is segmented into peritoneal dialysis, hemodialysis, and wearable artificial kidney for renal disease treatment.
Based on end-users
The renal disease market is segmented into dialysis centers, hospitals &clinics, research, and academic institutes.
Based on Region
Based on the region, the renal disease market is divided into four regions-America, Europe, Asia-Pacific, and the Middle East & Africa. Out of these, America is expected to be the highest market share among the others. Europe is expected to be the second-largest and Asia-Pacific is to be the fastest-growing region in the global market over the forecast period.
Regional Analysis -
Based on the region, the renal disease market is divided into four main regions- America, Europe, Asia-Pacific, and the Middle East & Africa.
Due to the increasing prevalence of renal disease causes to the geriatric population and the high availability of advanced features in North America, America is expected to the largest market share in the renal disease market. Europe is expected to be the second-largest share of the renal disease market for its high awareness of renal diseases, the government extended recommendations for dialysis, and the elderly population growth. In Europe, there is a rise in demand for diagnostic tests. In 2015, 10% of people are affected by CKD.
Due to the presence of developing economies like India, China, and South Korea, Asia-Pacific is expected to be the fastest-growing region in the market. These countries are highly demandable for the outsourcing of drug manufacturing, clinical trials, and pathology testing. Due to the high prevalence of renal disease in Saudi Arabia, Kuwait, and the UAE, the Middle East & Africa are expected to grow in the market.
The prominent key players in the renal disease market are as follows:
These key players are focussing on the launch of new developments, innovation, mergers, and acquisitions. Fresenius Medical Care is one of the leading companies that introduce new developments with advanced features.
The full report is inclusive of the following:
The research in the segmentation of the renal disease market is done based on treatment, end-users, and region.
By Disease Type
Chronic Kidney Disease, end-stage renal disease
By Treatment Type
Dialysis, medication, and kidney transplantation
Dialysis centers, hospitals & clinics, research, and academic institutes
America, Europe, Asia-Pacific, and Middle-East & Africa
|Market Size||USD 89,070 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Disease Type, Treatment Type, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Abbott (US), Amgen Inc (US), AstraZeneca (US), Bristol-Myers Squibb Company (US), Hoffmann- La Roche Ltd (Switzerland), Fresenius Medical Care AG & Co., Ltd (Japan), Novartis AG (Switzerland), Pfizer Inc. (US), Sanofi SA (France) and Teva Pharmaceutical Industries Ltd (Israel)|
|Key Market Opportunities||Expansion in Developing Economies|
|Key Market Drivers||Diagnosis of Blood Test for high growth|
Renal disease market projected to grow at approximately 11.20% CAGR during the assessment period (2022-2030).
The valuation of the renal disease market is estimated to increase to USD 89,070 Million by the end of 2030.
Growth in the prevalence of kidney diseases and the rising government funding for R&D & initiatives to spread the awareness, are major tailwinds pushing the growth of the global renal disease market.
North America holds the largest share in the global renal disease market, followed by Europe and the Asia Pacific, respectively.
Amgen Inc. (US), AstraZeneca (US), Abbott (US), Bristol-Myers Squibb Company (US), Fresenius Medical Care AG & Co. KGaA (UK), Teva Pharmaceutical Industries Ltd (Israel), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Kissei Pharmaceutical Co., Ltd (Japan), Keryx Biopharmaceuticals, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), and Sanofi SA (France), are some of the top players operating in the global renal disease market.